The sensitivity of the murine KRASG12C lung cancer cell lines to the KRASG12C inhibitors MRTX-1257 and AMG-510 as well as the MEK1/2 inhibitor, trametinib was assessed with in vitro growth assays (see Materials and Methods). Here, MAP2K1 is linked to lung carcinoma.